(PNTG) Pennant - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US70805E1091
PNTG: Healthcare, Home, Hospice, Senior, Living, Services
The Pennant Group, Inc. is a healthcare services provider operating in the United States, with a focus on delivering high-quality care to patients in various settings. The company's operations are divided into two primary segments: Home Health and Hospice Services, and Senior Living Services. Through its Home Health and Hospice Services segment, the company offers a range of clinical services, including nursing, speech, occupational, and physical therapy, as well as medical social work and home health aide services, all designed to support patients in the comfort of their own homes. Additionally, the company provides hospice services, which encompass clinical care, education, and counseling services tailored to the physical, spiritual, and psychosocial needs of terminally ill patients and their families.
The Senior Living Services segment of the company provides residential accommodations, activities, meals, housekeeping, and assistance with daily living tasks to seniors who are independent or require some level of support. This range of services enables seniors to maintain their independence and quality of life, while also receiving the care and support they need. The company operates a network of home health, hospice, and home care agencies, as well as senior living communities, across 13 states, including Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. This diverse geographic footprint allows the company to deliver its services to a wide range of patients and communities, while also leveraging its scale and expertise to drive operational efficiency and quality of care.
As a relatively new company, incorporated in 2019, The Pennant Group, Inc. is headquartered in Eagle, Idaho, and has established itself as a significant player in the healthcare services sector. With a strong focus on delivering patient-centered care and supporting the needs of seniors and terminally ill patients, the company is well-positioned for growth and expansion in the years to come. The company's common stock is listed on the NASDAQ exchange under the ticker symbol PNTG, and its web presence can be found at https://www.pennantgroup.com. The company's ISIN is US70805E1091, and it is classified within the Health Care Facilities sub-industry, reflecting its role as a provider of healthcare services and support to patients in a range of settings.
Additional Sources for PNTG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PNTG Stock Overview
Market Cap in USD | 935m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2019-10-01 |
PNTG Stock Ratings
Growth 5y | -1.05% |
Fundamental | 29.6% |
Dividend | - |
Rel. Strength Industry | 4093 |
Analysts | 4/5 |
Fair Price Momentum | 27.30 USD |
Fair Price DCF | 3.08 USD |
PNTG Dividends
No Dividends PaidPNTG Growth Ratios
Growth Correlation 3m | -94.8% |
Growth Correlation 12m | 81.9% |
Growth Correlation 5y | -36% |
CAGR 5y | -1.07% |
CAGR/Mean DD 5y | -0.02 |
Sharpe Ratio 12m | 1.54 |
Alpha | 40.50 |
Beta | 1.42 |
Volatility | 41.05% |
Current Volume | 160.3k |
Average Volume 20d | 254.9k |
As of January 21, 2025, the stock is trading at USD 27.46 with a total of 160,260 shares traded.
Over the past week, the price has changed by +4.69%, over one month by +0.29%, over three months by -16.41% and over the past year by +69.93%.
Neither. Based on ValueRay Fundamental Analyses, Pennant is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.57 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PNTG as of January 2025 is 27.30. This means that PNTG is currently overvalued and has a potential downside of -0.58%.
Pennant has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy PNTG.
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PNTG Pennant will be worth about 30.5 in January 2026. The stock is currently trading at 27.46. This means that the stock has a potential upside of +11.14%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 36 | 31.1% |
Analysts Target Price | 36 | 31.1% |
ValueRay Target Price | 30.5 | 11.1% |